Veryan Medical

Veryan Medical is a commercial-stage medical device company focused on revolutionizing peripheral artery disease (PAD) treatment through its proprietary BioMimics 3D helical stent technology. The stent's design, based on pioneering research from Imperial College London, aims to improve long-term patency by promoting beneficial swirling blood flow, which may reduce restenosis and stent failure. With FDA and CE Mark approvals, the company is commercializing its flagship product, supported by a growing body of clinical evidence from its MIMICS registry program. As part of Otsuka Medical Devices, Veryan leverages the resources of a larger healthcare group to expand its market reach.

BioMimics 3D platform: Design and manufacture of nitinol stents with a unique three-dimensional helical geometry that imparts a helical shape to the artery, promoting beneficial swirling blood flow to reduce restenosis.

Veryan competes in the crowded peripheral stent market against major players like Boston Scientific, Medtronic, and Abbott, who offer drug-eluting stents, drug-coated balloons, and bioresorbable scaffolds. Its differentiation is purely biomechanical (3D helical design) rather than pharmacological, positioning it in a unique but unproven niche against the drug-eluting standard of care.